Skip to main content

J&J Appeals To Mo. Supreme Court Over $2.1B Talc Verdict

J&J Appeals To Mo. Supreme Court Over $2.1B Talc Verdict

J&J Appeals To Mo. Supreme Court Over $2.1B Talc Verdict

Introduction

Last Wednesday, Johnson & Johnson (J&J) filed an application for transfer asking the Missouri Supreme Court to reverse the $2.1 billion talc verdict, stating that the lower courts misapplied the law and improperly combined nearly two dozen cases from around the country into a single trial despite a U.S. Supreme Court decision prohibiting the practice.

According to the filing, J&J maintained that the verdict “unconstitutionally punishes the defendant for purported harms to nonparties and acts in other jurisdictions.” The defendant argued that although the appeals court slashed the original $4.7 billion verdict, it failed to correct errors by the trial judge, further noting that this failure could result in more unfair trials in the future.

The case involves a group of 22 women who allege J&J's talcum powder products for causing cancer. The initial verdict favoring the plaintiffs was given in July 2018 by a state court jury. J&J appealed over the decision, following which the Missouri appeals court reduced the damages award to $2.1 billion in June 2020.

The defendant also noted that despite a U.S. Supreme Court decision the year before limiting the jurisdiction of state courts over out-of-state claims, Judge Rex Burlison allowed the out-of-state plaintiffs' cases into his St. Louis court. The plaintiffs did not have any connection with Missouri, yet Judge Burlison asserted jurisdiction claiming that the company had briefly distributed talcum powder from a Missouri supplier. 

Talc, one of the main ingredients in baby powder, is considered cosmetic when used in makeup and body powders, which required very little federal oversight. The law does not require cosmetic companies to share their safety information with the Food and Drug Administration (FDA). Without sound scientific data to show that it is harmful under its intended use, the FDA cannot take any action.

Despite several studies highlighting the cancer risk, the FDA does not require Baby Powder warnings on talc-based product labels to be updated. Moreover, J&J has also refused to add one, willingly.

J&J is facing several lawsuits against its talcum powder products, each raising similar claims about the presence of asbestos and the risk of cancer. The company is concerned that the decision could order up more multi-plaintiff trials despite the new law.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

Purdue, Sacklers Agree to New $7.4B Opioid Settlement

Categories: Opioids

All 50 U.S. states, along with the District of Columbia and U.S. territories, have agreed to a $7.4 billion settlement with Purdue Pharma, the manufacturer of OxyContin.

This deal addresses allegations that the company’s aggressive and…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!